SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Storey Robert F.)
 

Search: WFRF:(Storey Robert F.) > (2015-2019) > James Stefan K > Other academic/artistic > Fibrin clot propert...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome : a PLATO substudy

Sumaya, Wael (author)
Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
Wallentin, Lars, 1943- (author)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
James, Stefan K., 1964- (author)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
show more...
Siegbahn, Agneta, 1947- (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Klinisk kemi
Gabrysch, Katja (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Bertilsson, Maria (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Himmelmann, Anders (author)
AstraZeneca Res & Dev, Gothenburg, Sweden.
Ajjan, Ramzi A. (author)
Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, W Yorkshire, England.
Storey, Robert F. (author)
Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
show less...
Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England Kardiologi (creator_code:org_t)
2018-01-29
2018
English.
In: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 39:13, s. 1078-1085
  • Journal article (other academic/artistic)
Abstract Subject headings
Close  
  • Aims To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syndrome (ACS).Methods and results Plasma samples were collected at hospital discharge from 4354 ACS patients randomized to clopidogrel or ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. A validated turbidimetric assay was employed to study plasma clot lysis time and maximum turbidity (a measure of clot density). One-year rates of cardiovascular (CV) death, spontaneous myocardial infarction (MI) and PLATO-defined major bleeding events were assessed after sample collection. Hazard ratios (HRs) were estimated using Cox proportional hazards models. After adjusting for CV risk factors, each 50% increase in lysis time was associated with CV death/spontaneous MI [HR 1.17, 95% confidence interval (CI) 1.05-1.31; P < 0.01] and CV death alone (HR 1.36, 95% CI 1.17-1.59; P < 0.001). Similarly, each 50% increase in maximum turbidity was associated with increased risk of CV death (HR 1.24, 95% CI 1.03-1.50; P = 0.024). After adjustment for other prognostic biomarkers (leukocyte count, high-sensitivity C-reactive protein, high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide, and growth differentiation factor15), the association with CV death remained significant for lysis time (HR 1.2, 95% CI 1.01-1.42; P = 0.042) but not for maximum turbidity. These associations were consistent regardless of randomized antiplatelet treatment (all interaction P > 0.05). Neither lysis time nor maximum turbidity was associated with major bleeding events.Conclusion Fibrin clots that are resistant to lysis independently predict adverse outcome in ACS patients. Novel therapies targeting fibrin clot properties might be a new avenue for improving prognosis in patients with ACS.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

Acute coronary syndrome
Fibrin clot
Lysis time
Biomarker

Publication and Content Type

vet (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view